Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Breast cancer

E75—a safe and effective vaccine for the prevention of disease recurrence

Nature Reviews Clinical Oncology volume 11, page 440 (2014)Cite this article

Subjects

Breast cancer is the most common malignancy in women and even after curative treatment, approximately 10–20% of breast cancer survivors will develop disease recurrence. A recent study, published in the Annals of Oncology, reports that administration of the E75 vaccine (nelipepimut-S) in the adjuvant setting is safe and effective in preventing disease recurrence in disease-free patients at high-risk of breast cancer relapse.

E75 is a HER2-derived peptide that can elicit a specific immune response. Mittendorf and colleagues have used this peptide in combination with an immunoadjuvant—the granulocyte-macrophage colony-stimulating factor (GM-CSF)—and have conducted phase I/II trials to document the safety, immunogenicity and clinical efficacy of the E75 vaccine.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mittendorf, E. A. et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann. Oncol. 10.1093/annonc/mdu211

Download references

Authors
  1. Alessia Errico
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Errico, A. E75—a safe and effective vaccine for the prevention of disease recurrence. Nat Rev Clin Oncol 11, 440 (2014). https://doi.org/10.1038/nrclinonc.2014.110

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.110

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer